In addition, high SIGLEC9 expression presented to have a shorter survival probability in patients with age ≧60 years, with grade IV glioma, with GBM, with ATRX loss glioma, without radiotherapy, or without chemotherapy. This evidence concerns the gene SIGLEC9 and glioblastoma.